NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
- Conditions
- Recurrent MelanomaStage IIIA Skin MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaStage IV Skin Melanoma
- Interventions
- Biological: AldesleukinOther: Quality-of-Life AssessmentBiological: gp100 AntigenOther: Questionnaire AdministrationOther: Laboratory Biomarker Analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 185
- Registration Number
- NCT00019682
- Locations
- 🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
- Conditions
- Adult Solid Neoplasm
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00045201
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 589
- Registration Number
- NCT00004859
- Locations
- 🇺🇸
Sletten Regional Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸Doctors Hospital at Ohio Health, Columbus, Ohio, United States
🇺🇸Swedish Covenant Hospital, Chicago, Illinois, United States
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
- Conditions
- Untreated Childhood GliosarcomaUntreated Childhood Anaplastic OligodendrogliomaUntreated Childhood Anaplastic AstrocytomaUntreated Childhood Brain Stem GliomaUntreated Childhood Giant Cell GlioblastomaUntreated Childhood GlioblastomaUntreated Childhood Gliomatosis CerebriUntreated Childhood Oligodendroglioma
- Interventions
- Radiation: radiation therapyOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 69
- Registration Number
- NCT00042991
- Locations
- 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States
Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
- Conditions
- Recurrent Ovarian Epithelial CancerPrimary Peritoneal Cavity CancerStage IV Ovarian Epithelial Cancer
- Interventions
- Biological: bevacizumabOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00022659
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3000
- Registration Number
- NCT00031928
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States
Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020488
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer
- Conditions
- Lung CancerHead and Neck Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019201
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019136
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer
- Conditions
- Stage IV Breast CancerRecurrent Breast Cancer
- Interventions
- Other: laboratory biomarker analysisBiological: trastuzumab
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 84
- Registration Number
- NCT00004888
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States